The American Dental Association has released new guidelines for patients receiving antiresorptive therapy for the prevention and treatment of osteoporosis, entitled “Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis.”

These new recommendations are posted on the ADA’s website, and a summary appears in the November 2011 issue of the Journal of the American Dental Association.

The new recommendations guide dentists and dental professionals away from the perception that intravenous bisphosphonates could cause osteonecrosis of the jaw.

As reported in Medscape News, the new guidelines won praise from Jeffrey Fellows, PhD, an investigator at the Kaiser Permanente Center for Health Research and lead author of a recent study on osteonecrosis of the jaw published in Clinical Medicine and Research.

“I think that they are all good recommendations,” Dr. Fellows, who did not serve on the ADA committee, told Medscape Medical News.

For more on this story and the recommendations see: American Dental Association Updates Osteonecrosis Guidelines